Procalcitonin Monitoring Sepsis Study

Procalcitonin Decrease Over 72 Hours and Outcome in Patients With Severe Sepsis or Septic Shock

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01523717

Acronym

MOSES

Enrollment

858

Registered

2012-02-01

Start date

2011-12-31

Completion date

2014-03-31

Last updated

2015-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic Shock, Severe Sepsis

Keywords

procalcitonin, decrease over 72 hours, severe sepsis, septic shock

Brief summary

The purpose of this study is to investigate the relationship between a procalcitonin decrease over 72 hours and outcome in patients who have severe sepsis or septic shock.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients (i.e. \>18 years of age) diagnosed with severe sepsis or septic shock as defined in Appendix 1, who are already in the ICU or come from the ED, other wards or directly from out of hospital * Blood sample collection within 12 hours after diagnosis severe sepsis or septic shockNo prior enrollment into this study * Written informed consent

Design outcomes

Primary

Measure	Time frame	Description
28 day all cause mortality	within 28 day safter inlclusion	participants will be followed up for 28 days

Secondary

Measure	Time frame	Description
all-cause in-hospital mortality	mortality during hospital stay	count all death through out stay in the hospital

Countries

United States

Outcome results